Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients

Andromachi Scaradavou(NewYork–Presbyterian Hospital), James B. Bussel(Cornell University), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Lawrence J. Ettinger(Saint Peter's University Hospital), Susanna Cunningham–Rundles(NewYork–Presbyterian Hospital), Bonnie Woo(NewYork–Presbyterian Hospital), B.M.R.N.J. Woloski(NewYork–Presbyterian Hospital)
Blood
April 15, 1997
10.1182/blood.v89.8.2689
Cited by 318

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587